Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089388 · ClinicalTrials.gov registry record · Phase 2
Cilengitide in Treating Patients With Acute Myeloid Leukemia
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00089388: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00089388 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 70 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00089388, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying how well cilengitide works in treating patients with acute myeloid leukemia. Cilengitide may stop the growth of cancer cells by blocking the enzymes necessary for their growth
Interventions
- DRUG cilengitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2004-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00089388
The ClinicalTrials.gov registry entry for NCT00089388 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cilengitide is the first listed.
NCT00089388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00089388 about?
NCT00089388 is a clinical study titled "Cilengitide in Treating Patients With Acute Myeloid Leukemia". This randomized phase II trial is studying how well cilengitide works in treating patients with acute myeloid leukemia. Cilengitide may stop the growth of cancer cells by blocking the enzymes necessary for their growth
What is the current status of trial NCT00089388?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2004-07.
What interventions are being tested in trial NCT00089388?
The interventions under investigation include: cilengitide (DRUG).
Who is sponsoring clinical trial NCT00089388?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.